Civil Law And Bio Digital Hybrid Property Human Genetic Digital Asset Fusion In Uae .
1. Introduction
Bio-digital hybrid property refers to the legal and economic interests created when human biological materials, genetic information, biotechnology, artificial intelligence and digital assets become interconnected.
In the United Arab Emirates (UAE), this emerging area raises important questions concerning ownership, privacy, contractual rights, inheritance, intellectual property, commercial exploitation and civil liability.
Examples include:
Digitized human genetic information stored on blockchain networks.
DNA databases linked to digital identity systems.
Genomic datasets used to train artificial intelligence models.
Biometric and genetic information incorporated into digital health platforms.
Commercial licensing of genetic datasets for pharmaceutical research.
Tokenization of rights associated with biological samples or genomic research.
Digital representations of human biological characteristics used in personalized medicine.
Central legal question: Can human genetic material and its digitally generated information be treated as transferable property, or should they remain subject to personal rights, privacy protections and restrictions on commercial exploitation?
The UAE does not currently provide a single, comprehensive statutory category called bio-digital hybrid property. Its legal treatment must therefore be developed by combining civil law, personal rights, data protection, healthcare regulation, intellectual property and contractual principles.
2. UAE statutory and regulatory framework
A. Federal Law by Decree No. 49 of 2023 – Regulation of the Use of the Human Genome
This is the most directly relevant legislation.
The law establishes safeguards for human genetic and genomic information.
Important provisions include:
| Provision | Legal significance |
|---|---|
| Article 2 | Applies to human genome-related uses throughout the UAE, including free zones. |
| Article 3 | Protects human dignity, private life, confidentiality and public health. |
| Article 4 | Requires consent for genetic and genomic screening, subject to statutory provisions. |
| Article 6 | Regulates consent requirements. |
| Articles 16–17 | Restricts genomic alteration while providing for regulated gene therapy. |
| Article 23 | Addresses genetic screening for lineage and ethnic origins. |
| Article 25 | Protects confidentiality of genetic and genomic information and prohibits discriminatory uses. |
| Article 28 | Requires appropriate health-authority licensing for facilities dealing with human genome services. |
A particularly important distinction is that permission to analyse a biological sample does not automatically create ownership of the person's genome or unrestricted commercial rights over the resulting information.
Additional consent is required for certain secondary uses of collected biological samples. The law also regulates their storage, transfer and destruction.
B. Federal Decree-Law No. 45 of 2021 – Personal Data Protection Law
The Personal Data Protection Law (PDPL) provides a wider framework for personal information.
Genetic information and information concerning a person's physical, psychological and health condition fall within the sensitive-data concept.
Its important principles include:
Lawful and transparent processing.
Purpose limitation.
Data minimisation.
Appropriate information security.
Consent and other legally recognised processing grounds.
Rights concerning correction and restriction or cessation of processing.
Controls on cross-border transfers.
However, an important jurisdictional qualification applies: Article 2 excludes certain categories, including personal health data regulated by separate legislation and entities in free zones with their own data-protection regimes. Therefore, the PDPL must not be treated as the only applicable framework for genomic health information.
C. Federal Law No. 2 of 2019 – Use of Information and Communication Technology in Health Fields
This legislation is relevant to electronic health records, digital medical information, healthcare systems and the handling of health information.
It becomes particularly important where genomic information is stored in electronic medical databases or shared between healthcare providers.
D. Federal Decree-Law No. 39 of 2023 – Federal DNA Fingerprinting Database
This law provides a separate framework for the federal DNA fingerprinting database.
It is important to distinguish forensic DNA profiling from voluntary genetic research and commercial genomic databases. Their purposes, access rights and legal controls are not identical.
E. UAE Civil Transactions Law – Federal Law No. 5 of 1985
The Civil Transactions Law supplies the general principles governing property, obligations, contracts, civil responsibility and compensation.
Articles 97–98 are particularly relevant to the classification of property.
Article 97 recognises things capable of possession or lawful enjoyment, provided they are not excluded from legal transactions by their nature or by law.
Article 98 recognises that certain things are inherently outside exclusive possession or are excluded from transactions by law.
These provisions create an important legal question: whether a digital genomic dataset, biological sample or commercially developed genetic product is capable of being treated as an independent proprietary asset.
The answer depends on the nature of the asset and the applicable statutory restrictions.
3. Legal nature of bio-digital hybrid property
The subject can be divided into five legally distinct categories.
A. Physical biological materials
These include:
Blood samples.
Human tissue.
Hair and other biological specimens.
Reproductive materials.
Cells and extracted DNA.
Stored biological samples in biobanks.
The legal issue is whether a person retains proprietary rights after voluntarily providing a sample to a hospital, research institution or biotechnology company.
The UAE Human Genome Law regulates the collection, use, storage and transfer of biological samples. It does not establish unrestricted private ownership of human biological material.
B. Genetic and genomic information
This category includes:
DNA sequences.
Genetic variations.
Hereditary disease information.
Genome sequencing results.
Ancestry and lineage information.
Predictive genetic information.
Genetic information is particularly sensitive because it can reveal information about both the individual and biological relatives.
Under Article 25 of Federal Law by Decree No. 49 of 2023, genetic and genomic information must remain confidential and cannot be used to discriminate against individuals on the basis of genetic characteristics, ethnic origins or lineage.
Consequently, genetic information cannot simply be treated as an ordinary commercial database.
C. Digitally generated genetic assets
Examples include:
Digitized genome sequences.
Computational genetic models.
AI-generated genomic predictions.
Digital genetic research databases.
Genomic algorithms.
Artificially generated molecular structures.
A distinction must be maintained between the original genetic information and the independently developed technological product.
For example, a biotechnology company may develop a proprietary algorithm using lawfully obtained genomic information. The algorithm may qualify for intellectual property protection if the applicable requirements are satisfied.
However, this does not automatically give the company ownership of the individuals' underlying genetic identities.
D. Tokenized biological and genomic interests
A blockchain platform might create digital tokens representing:
Participation in a genetic research programme.
Contractual rights to research benefits.
Licensed access to anonymized genomic datasets.
Royalties from a permitted biotechnology invention.
Rights to receive payments under a research agreement.
Such tokens should be distinguished from ownership of the human body, DNA or genetic identity.
A token cannot independently legalize an otherwise prohibited use of biological material or sensitive personal information.
E. Integrated bio-digital assets
The most advanced category involves a combination of:
A physical biological sample.
A digitized genomic sequence.
An AI-generated biological prediction.
A blockchain-based record.
A commercial licensing agreement.
This produces a hybrid legal object involving several independent rights rather than one unified property right.
4. Ownership and proprietary rights under UAE civil law
The central question is whether genetic and digital information can satisfy the requirements of property under the UAE Civil Transactions Law.
Article 97 provides the foundation for recognising property capable of possession or lawful enjoyment.
However, three separate interests must be considered.
| Interest | Possible legal treatment |
|---|---|
| Biological sample | Subject to human genome legislation, consent and healthcare regulation |
| Genetic information | Protected confidential and sensitive information |
| Independently developed digital technology | Potential intellectual property or contractual asset |
A. No automatic ownership transfer through consent
A person who provides a blood sample for medical research does not necessarily transfer every legal interest in the resulting genetic information.
Consent should identify:
The purpose of collection.
The intended research.
The permitted secondary uses.
Storage duration.
Access and disclosure arrangements.
Whether commercial development is contemplated.
Whether data will be shared internationally.
The UAE's Human Genome Law specifically requires renewed written consent for certain additional uses of collected biological samples.
B. Commercial ownership of derived products
A biotechnology company may develop a diagnostic method, software platform or synthetic biological product using lawfully obtained genetic information.
The resulting invention or software may generate independent intellectual property rights.
Nevertheless, four things must not be confused:
Ownership of the laboratory equipment.
Ownership or control of the research institution's database.
Intellectual property in an independently developed invention.
Personal rights concerning the human genetic information used in development.
The existence of one does not automatically establish the others.
C. Genetic identity and personal rights
Genetic identity has a close relationship with human dignity, personal privacy and family identity.
Therefore, a commercial agreement purporting to transfer permanent and unrestricted control over a person's genetic identity would raise serious legal and public-policy questions.
In particular, contractual freedom cannot override mandatory protections under UAE legislation.
5. Bio-digital hybrid property and contract law
Contract law becomes important when genetic materials and digital representations are supplied to research institutions or commercial enterprises.
Potential contractual arrangements include:
1. Genomic research agreements
These establish the permitted purposes of research and the conditions for collecting and processing biological materials.
2. Genetic data licensing agreements
These regulate access to and use of genomic datasets.
3. Biotechnology development agreements
These establish ownership and licensing arrangements concerning independently developed inventions and technology.
4. Digital asset agreements
These regulate blockchain-based representations of contractual or economic rights.
5. Biobank custody agreements
These establish responsibilities concerning storage, security, preservation, transfer and destruction of biological samples.
Good faith and contractual performance
The general principles of the UAE Civil Transactions Law concerning contractual obligations, good faith and performance are relevant.
A research institution should not use a narrow interpretation of a consent form to justify an entirely different purpose where the applicable legislation requires further consent.
For example, a patient may consent to genetic testing for diagnosis but not to unrestricted commercial licensing of identifiable genomic information.
The distinction between medical consent and commercial authorization is fundamental.
6. Digital asset and blockchain integration
How advances in genomics will change medicine in general practice | GPonline
제약·바이오업계 "AI개발자 모십니다" : 네이트 뉴스
9
Blockchain can be used to maintain records concerning genomic information without necessarily storing the underlying genetic data on the blockchain.
A legally safer architecture would involve:
Keeping identifiable genetic information in a secured, access-controlled database.
Storing only appropriate cryptographic references or audit records on the blockchain.
Recording the purposes for which data may be accessed.
Maintaining consent and authorization records.
Restricting unauthorized secondary use.
Establishing procedures for withdrawal, correction and deletion where legally required.
The immutability problem
Blockchain records may be difficult to modify or erase.
This creates a potential conflict with personal-data protection requirements and the individual's rights.
A blockchain entry showing that consent was given does not mean that consent can never be withdrawn.
A more suitable system would retain the actual genetic information off-chain and use revocable access permissions.
Smart contracts
Smart contracts may automate:
Research licensing payments.
Royalty distribution.
Access authorization.
Research participation payments.
Contractual benefit-sharing.
However, smart-contract execution cannot replace mandatory human genome legislation, medical authorization or legally required consent.
7. Intellectual property and genetic innovation
The UAE's intellectual property framework must be considered alongside its human genome legislation.
A useful distinction exists between naturally occurring genetic material and technological inventions developed through human innovation.
| Subject | Potential legal position |
|---|---|
| Naturally occurring human DNA | Not automatically a privately owned invention |
| Isolated genetic sequence | Cannot automatically be monopolized merely because it has been isolated |
| Artificially developed genetic construct | May qualify for protection if statutory requirements are met |
| Genomic research software | May receive copyright protection |
| Original genomic database structure | May receive applicable intellectual property protection |
| Genetic research methodology | Protection depends on the nature of the claimed invention |
| AI-generated genetic predictions | Depends on applicable intellectual property requirements and human contribution |
An important principle is that the commercialization of a technological invention does not automatically create ownership over the underlying human genetic information.
8. At least six important judicial decisions
Important jurisdictional clarification: The following are comparative foreign judicial decisions, not UAE precedents. They are useful because UAE courts may face similar questions concerning biological samples, genetic information, commercial exploitation, property classification and digital innovation. They must not be presented as binding UAE judgments.
Case 1. Moore v. Regents of the University of California (1990)
Supreme Court of California · 51 Cal. 3d 120
Facts:
John Moore underwent medical treatment. His physician used cells obtained from his body to develop a commercially valuable cell line without adequately disclosing the research and economic interests involved.
Judgment:
The court rejected Moore's conversion claim based on ownership of the removed cells. However, it recognised the importance of the physician's disclosure obligations and allowed other claims, including breach of fiduciary duty, to proceed.
Legal principle:
The commercial development of biological materials does not necessarily establish ownership rights in the original biological material for the patient.
UAE relevance:
This case helps distinguish ownership of a biological sample from duties relating to consent, disclosure and confidentiality. In the UAE, the Human Genome Law provides specific statutory safeguards that must be respected.
Case 2. Greenberg v. Miami Children's Hospital Research Institute (2003)
United States District Court, Southern District of Florida · 264 F. Supp. 2d 1064
Facts:
Families affected by Canavan disease provided biological samples and assistance for genetic research. The researcher identified the relevant gene and obtained patent protection. Commercial licensing subsequently restricted access to testing.
Judgment:
The court dismissed several claims, including conversion, informed consent and breach of fiduciary duty, but allowed the unjust enrichment claim to proceed.
Legal principle:
Research commercialization can raise restitutionary questions even when the donors cannot establish conventional ownership of donated biological material.
UAE relevance:
A genomic research company could face civil claims where commercial exploitation violates contractual expectations or produces an unjustified benefit at the expense of contributors.
Case 3. Washington University v. Catalona (2007)
United States Court of Appeals for the Eighth Circuit · 490 F.3d 667
Facts:
Dr. William Catalona collected biological materials from patients for prostate cancer research at Washington University. A dispute arose concerning ownership and the transfer of samples when he left the university.
Judgment:
The appellate court upheld the finding that Washington University owned the samples because the donors had made valid gifts to the institution.
Legal principle:
The legal consequences of biological sample donation depend substantially on the consent documents, the circumstances of donation and the institution's rights.
UAE relevance:
This decision demonstrates why UAE biobanks and research institutions should maintain clear sample-custody agreements and consent documentation.
Case 4. Yearworth v. North Bristol NHS Trust (2009)
England and Wales Court of Appeal · [2009] EWCA Civ 37
Facts:
Several men undergoing cancer treatment deposited sperm samples for future reproductive use. The hospital negligently failed to preserve them.
Judgment:
The Court of Appeal recognised that the stored sperm constituted property belonging to the men for the purposes of their negligence and bailment claims.
Legal principle:
Certain biological materials may attract proprietary protection where their preservation and use have particular personal significance.
UAE relevance:
The decision provides a useful analogy for stored reproductive material, biobank custody and compensation for negligent destruction of biological samples.
Case 5. Hecht v. Superior Court (1993)
California Court of Appeal · 20 Cal. Rptr. 2d 275
Facts:
A man stored sperm before his death and expressed his intention that his partner should be able to use it for reproductive purposes.
After his death, a dispute arose over the legal status and disposition of the stored sperm.
Judgment:
The court recognised that the sperm could constitute property for the limited purposes of the relevant probate proceedings.
Legal principle:
Biological reproductive materials may have legally recognised interests involving personal autonomy and succession.
UAE relevance:
This case raises important questions about reproductive materials, inheritance, personal status and the legal consequences of death. Any UAE application must additionally respect UAE reproductive medicine and personal-status legislation.
Case 6. Association for Molecular Pathology v. Myriad Genetics (2013)
United States Supreme Court · 569 U.S. 576
Facts:
Myriad Genetics identified the BRCA1 and BRCA2 genes associated with increased risks of breast and ovarian cancer and obtained patents relating to them.
Judgment:
The Supreme Court held that naturally occurring DNA segments were not patentable merely because they had been isolated. However, synthetically created complementary DNA (cDNA) could qualify for patent protection because it was not naturally occurring, subject to the qualifications in the judgment.
Legal principle:
Discovering naturally occurring genetic information is different from creating a new technological invention.
UAE relevance:
This distinction is important when determining whether a biotechnology company can claim intellectual property rights over genomic research products without claiming ownership over the individual's naturally occurring genetic identity.
Comparative significance
| Case | Principal legal issue | Application to UAE analysis |
|---|---|---|
| Moore | Biological material ownership | Patient rights and commercialization |
| Greenberg | Unjust enrichment | Commercial research benefits |
| Catalona | Biobank ownership | Sample custody and donation |
| Yearworth | Biological material as property | Negligent preservation |
| Hecht | Reproductive material and succession | Inheritance and personal autonomy |
| Myriad | Genetic patent eligibility | Limits on genetic monopolies |
These decisions collectively demonstrate that biological materials, genetic information and biotechnology inventions should not automatically be treated as one indivisible property category.
Additional comparative authority includes Brotherton v. Cleveland (1991), which examined property-like interests in human tissue, and Cruzan v. Director, Missouri Department of Health (1990), concerning personal autonomy and medical decision-making.
9. Civil liability for misuse of bio-digital property
The integration of genetic and digital information creates several possible categories of civil liability.
A. Unauthorized genetic data processing
A healthcare institution may incur legal responsibility if it processes genetic information without the required authorization or outside the permitted purpose.
Examples:
Unauthorized genomic profiling.
Disclosure of genetic test results.
Commercial sale of identifiable genetic information.
Unauthorized sharing with foreign research institutions.
B. Negligent destruction of biological materials
A biobank may be liable where negligent storage causes the destruction of valuable biological samples.
Relevant circumstances include:
Failure of cryogenic storage systems.
Inadequate temperature monitoring.
Improper sample identification.
Negligent transportation.
Failure to maintain backup preservation systems.
The Yearworth decision provides a comparative foundation for considering these claims.
C. AI-related genetic prediction errors
Suppose an AI system analyses genomic information and incorrectly predicts that an individual has a hereditary disease.
Potential consequences include:
Unnecessary medical treatment.
Psychological harm.
Financial losses.
Incorrect medical records.
Improper disclosure to third parties.
Civil liability may arise from negligent medical practice, defective systems, contractual breaches or unlawful data processing, depending on the circumstances.
D. Blockchain-related liability
A digital platform may face liability for:
Unauthorized transfer of genomic access tokens.
Incorrect execution of smart contracts.
Exposure of confidential genetic information.
Inadequate cybersecurity.
Unauthorized licensing of research datasets.
The operator cannot avoid responsibility merely because the transaction was executed automatically.
10. Inheritance and succession of bio-digital hybrid assets
An important emerging question concerns what happens to genetic and digital interests after the death of an individual.
Three categories must be distinguished.
| Asset or interest | Succession implications |
|---|---|
| Cryptocurrency and ordinary digital assets | May form part of an estate subject to applicable succession law |
| Contractual royalty entitlements | May be inheritable depending on their legal nature |
| Stored reproductive materials | Subject to specific personal-status and reproductive legislation |
| Genetic information | Remains subject to confidentiality and statutory restrictions |
| Genetic identity | Cannot simply be transferred as an ordinary commercial asset |
| Biotechnology patents | May be transferable or inheritable under applicable IP and succession rules |
For example, if an individual participates in a genomic research project and receives contractual royalty entitlements from a resulting invention, the economic entitlement may raise ordinary succession questions.
However, the individual's death does not automatically authorize unrestricted disclosure or commercial use of their genetic information.
11. Genetic discrimination and insurance
Genetic discrimination is a particularly significant concern.
An insurance company might attempt to obtain genetic information to estimate the likelihood of future disease.
The UAE's Human Genome Law addresses this issue directly.
Article 20 establishes restrictions concerning the use of genetic and genomic screening in insurance services, including restrictions on requiring prospective insured persons to undergo predictive genetic screening and requesting or using previous screening results.
The Dubai Health Authority's Standards for Human Genetic and Genomic Data and Information Governance, effective from 28 November 2025, also address insurance-related restrictions.
This is important because the economic value of genetic information must not undermine the individual's statutory protections.
12. Cross-border transactions and international genomic databases
Bio-digital property often involves international transactions.
For example:
A UAE hospital collects biological samples.
A foreign biotechnology company conducts genomic analysis.
An overseas cloud provider stores the resulting data.
An AI company uses permitted datasets for research.
A blockchain platform records licensing transactions.
This creates questions concerning:
Cross-border data transfers.
Foreign processing of genetic information.
Applicable contractual law.
Confidentiality obligations.
Regulatory approvals.
Jurisdiction over civil disputes.
Article 2 of Federal Law by Decree No. 49 of 2023 is especially significant because its scope extends to human genome-related uses in the UAE, including free zones.
The law also regulates the transfer and storage of biological samples outside the UAE, subject to the applicable exceptions and health-authority approvals.
The Personal Data Protection Law must be read alongside applicable health-data and free-zone legislation rather than assumed to apply identically to every genomic transaction.
13. Remedies available under UAE civil law
Depending on the cause of action and applicable legislation, affected individuals may seek:
1. Compensation
For legally established financial and non-financial harm.
2. Injunctions
To prevent continuing unauthorized use or disclosure where the applicable legal requirements are satisfied.
3. Contractual remedies
For breach of research agreements, licensing agreements or confidentiality obligations.
4. Restitution
Where the facts establish an actionable claim for unjust enrichment or another recognised restitutionary remedy.
5. Data-related remedies
Including correction and restriction or cessation of processing where the relevant data-protection legislation provides them.
6. Regulatory remedies
Complaints and enforcement proceedings before the competent health or data-protection authorities.
Civil remedies do not exclude separate administrative or criminal consequences where statutory violations occur.
14. Major legal challenges in the UAE
| Challenge | Legal concern | Possible regulatory response |
|---|---|---|
| Genomic ownership | Uncertainty over proprietary interests | Clear classification of biological and digital interests |
| Genetic commercialization | Unauthorized commercial exploitation | Detailed consent and licensing rules |
| Blockchain immutability | Difficulty correcting or deleting records | Off-chain sensitive-data storage |
| AI genomic profiling | Incorrect predictions and discrimination | Algorithmic oversight and accountability |
| Inheritance | Treatment of stored biological materials | Clear succession and personal-status rules |
| Biobank ownership | Disputes over sample custody | Standardized biobank agreements |
| Cross-border transfers | Loss of regulatory control | Strong transfer and authorization procedures |
| Genetic discrimination | Unfair treatment based on hereditary characteristics | Enforcement of statutory protections |
15. Proposed legal framework for bio-digital hybrid property in the UAE
A comprehensive approach could be developed around six principles.
Proposed six-pillar framework
Human biological autonomy
Biological materials and genetic identity must remain protected by human dignity, autonomy and applicable statutory restrictions.
Genomic data sovereignty
Individuals must receive meaningful protection concerning the collection, processing, disclosure and permitted uses of their genetic information.
Independent digital ownership
Independently developed software, inventions and technological products should be assessed under the applicable intellectual property framework.
Controlled commercialization
Commercial exploitation must comply with informed consent, licensing, research and healthcare requirements.
Digital transaction accountability
Blockchain operators, AI developers, research institutions and data processors should have clearly allocated legal responsibilities.
Succession and compensation
The law should clarify inheritable economic entitlements, custody responsibilities and compensation for wrongful destruction or misuse.
16. Illustrative legal scenario
Consider the following hypothetical situation.
A UAE biotechnology company collects biological samples from 5,000 individuals under a medical research programme. It digitizes their genetic information, trains an AI system and develops a predictive genetic testing platform.
The company subsequently creates blockchain tokens representing commercial access to the resulting research database.
Several legal questions arise:
| Dispute | Applicable legal principles |
|---|---|
| Participants challenge secondary use | Human Genome Law and consent requirements |
| Company claims ownership of all genetic information | Civil property principles and personal rights |
| Participants challenge commercial exploitation | Consent, contractual obligations and potential restitution |
| AI system exposes genetic information | Confidentiality, data protection and civil liability |
| Tokens are transferred without authorization | Contractual and digital asset rules |
| Participant dies with outstanding royalties | Succession and contractual rights |
The company may potentially own its independently developed software and qualifying intellectual property. It cannot automatically claim unrestricted ownership of all underlying genetic information merely because it created the digital platform.
17. Important statutory and judicial authorities
For academic and legal research, the principal authorities are:
UAE legislation
Federal Law No. 5 of 1985 – Civil Transactions Law.
Federal Law No. 2 of 2019 – Use of Information and Communication Technology in Health Fields.
Federal Decree-Law No. 45 of 2021 – Personal Data Protection Law.
Federal Decree-Law No. 39 of 2023 – Federal DNA Fingerprinting Database.
Federal Law by Decree No. 49 of 2023 – Regulation of the Use of the Human Genome.
Applicable UAE intellectual property and medical-products legislation.
Applicable emirate-level healthcare and data-governance regulations.
Comparative judicial authorities
Moore v. Regents of the University of California (1990).
Greenberg v. Miami Children's Hospital Research Institute (2003).
Washington University v. Catalona (2007).
Yearworth v. North Bristol NHS Trust (2009).
Hecht v. Superior Court (1993).
Association for Molecular Pathology v. Myriad Genetics (2013).
Brotherton v. Cleveland (1991).
Cruzan v. Director, Missouri Department of Health (1990).
18. Conclusion
Civil Law and Bio-Digital Hybrid Property in the UAE represents an emerging intersection of biotechnology, digital assets, personal rights and private law.
The most important legal distinction is between human genetic identity, biological materials, genomic information and independently developed digital intellectual property.
The UAE's Federal Law by Decree No. 49 of 2023 provides a particularly important statutory foundation by regulating human genome usage, consent, confidentiality, biological samples and genetic discrimination.
The Civil Transactions Law provides the general principles for property, contractual obligations and civil liability, while personal-data, healthcare and intellectual property legislation supplies additional protections.
The comparative cases of Moore, Greenberg, Catalona, Yearworth, Hecht and Myriad demonstrate that human biological material cannot always be treated like conventional commercial property.
The central legal proposition is that technological innovation may create commercially valuable digital and intellectual property, but it does not automatically convert human genetic identity into an unrestricted transferable commodity.
That distinction should form the foundation of any future UAE legal framework governing bio-digital hybrid property.

comments